Henry Hadad is Senior Vice President & Deputy General Counsel, Innovation Law, at Bristol Myers Squibb in Princeton, NJ, where he is Chief Intellectual Property (IP) Counsel, leading a team supporting the company’s efforts to discover, develop and deliver groundbreaking treatments for patients with serious unmet medical need.  He was previously Chief IP Counsel at Schering-Plough Corporation and held roles at Johnson & Johnson and in private practice.  During his legal career, Mr. Hadad has represented the innovative biopharmaceutical, generic, medical device and consumer goods industries, with a focus on IP procurement, litigation, transactions and policy in the United States and internationally, and is an active member of numerous IP educational, policy and advocacy organizations.  He is a board member of the Intellectual Property Owners (IPO) Association, served as its President (2018-2019), and is currently chair of its Amicus Committee.  In September 2022, Mr. Hadad received IPO’s Carl B. Horton Distinguished IP Service award for “extraordinary leadership and dedication to promoting the value of intellectual property to society and the global economy.”  In December 2022, he was appointed by the U.S. Secretary of Commerce to the Patent Public Advisory Committee (PPAC), which is charged with reviewing “policies, goals, performance, budget, and user fees” of the USPTO and advising the Director on these matters.   Mr. Hadad holds a B.S. in Biology from Haverford College and a J.D., cum laude, from the American University, Washington College of Law.

Andrew Jenner is Director General of Interpat – a global trade association of Chief IP Counsels from the biopharmaceutical industry that seeks create sustainable innovation ecosystems to advance human health. He has a passion for collaboration and finding solutions that work in both the short and long term. He is also the Executive Director of a global strategy and policy consultancy based in the UK and assists a range of clients on corporate affairs strategies, particularly in advancing economies.

He was previous the Executive Director of Corporate Strategy and Legal Affairs at the International Federation of Pharmaceutical Manufactures and Associations (IFPMA) based in Geneva, where he deputised for the Director General. His main responsibilities included developing pharmaceutical industry strategy and policy development on priority issues. He also represented the industry within the UN and the World Trade Organization, leading a diverse team of policy, public affairs and legal professionals.

From 2007 to 2009 he was a Senior Policy Advisor and Head of the IP Crime Policy Group for the UK Intellectual Property Office (IPO), and led on the creation and implementation of an interagency strategy to combat counterfeiting and piracy.

From 2004 to 2007 he was Head of Trade & Development at the IPO and led the UK delegation within the World Trade Organization and the World Intellectual Property Organization. He was also the principle IP advisor to the EU on the World Health Organization’s negotiations on Public Health, Innovation and IP. He also led on policy relating to EU/UK IP pharmaceutical regulations, including the EU Regulation on the compulsory licensing, and implementation of the EU Human Medicines and Paediatric Medicines Regulations into UK law. He first joined the UK Government in 1998 as a patent examiner in medical and optical devices having previously worked in the automotive industry.

He is Chartered Manager (CMGR), a Fellow of the Chartered Institute of Management (FCMI), a Fellow the Royal Society of Arts (FRSA) and a Member of the Institute of Engineering & Technology (MIET) having a bachelor’s degree (B.Eng (Hons)) in Mechanical Engineering, and a Post-graduate (PgD) and Master (LLM) degrees in Law.

Robert Stanley is the Global Head of Intellectual Property for the Novartis Group, responsible for all IP matters throughout the business, as a member of Novartis’s Legal Leadership Team and head of the IP Leadership Team. He joined Novartis in 2017 as the Global Head IP Litigation. Prior to joining Novartis, Robert was a Partner at Finnegan, Henderson, Farabow, Garrett & Dunner in Atlanta, Georgia, where he focused on pharmaceutical patent litigation as well as prosecution and counseling for patents and trademarks. Robert has a B.S. in chemistry and a B.A. in political science from Furman University in Greenville, South Carolina, and a J.D. cum laude from the University of Georgia.